Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sutro Biopharma (STRO) Preferred Stock Liabilities (2016 - 2018)

Sutro Biopharma's Preferred Stock Liabilities history spans 3 years, with the latest figure at $187.2 million for Q3 2018.

  • On a quarterly basis, Preferred Stock Liabilities changed N/A to $187.2 million in Q3 2018 year-over-year; TTM through Sep 2018 was $187.2 million, a N/A change, with the full-year FY2017 number at $102.5 million, changed 0.0% from a year prior.
  • Preferred Stock Liabilities hit $187.2 million in Q3 2018 for Sutro Biopharma, up from $102.5 million in the prior quarter.
  • Over the last five years, Preferred Stock Liabilities for STRO hit a ceiling of $187.2 million in Q3 2018 and a floor of $102.5 million in Q4 2016.
  • Historically, Preferred Stock Liabilities has averaged $130.8 million across 3 years, with a median of $102.5 million in 2016.
  • The widest YoY moves for Preferred Stock Liabilities: up 0.0% in 2017, down 0.0% in 2017.
  • Tracing STRO's Preferred Stock Liabilities over 3 years: stood at $102.5 million in 2016, then changed by 0.0% to $102.5 million in 2017, then surged by 82.67% to $187.2 million in 2018.
  • Business Quant data shows Preferred Stock Liabilities for STRO at $187.2 million in Q3 2018, $102.5 million in Q4 2017, and $102.5 million in Q4 2016.